Ductal carcinoma in situ: Trends in treatment over time in the US

Breast Cancer Research and Treatment

Volumn 127, Issue 1, 2011, Pages 251-257

  Zujewski, Jo Anne ^a   Harlan, Linda C ^a   Morrell, Donna M ^b   Stevens, Jennifer L ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

DCIS; Female; Hormonal therapy; Population based; Surgery; Treatment

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; TREND STUDY; TUMOR VOLUME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; SEER PROGRAM; UNITED STATES;

EID: 79954642383     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1198-z     Document Type: Article

References (17)

1. B Erbas E Provenzano J Armes D Gertig 2006 The natural history of ductal carcinoma in situ of the breast: a review Breast Cancer Res Treat 97 135 144 16319971 10.1007/s10549-005-9101-z
2. CJ Allegra DR Aberle P Ganschow, et al. 2010 National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ September 22-24, 2009 J Natl Cancer Inst 102 161 169 20071686 10.1093/jnci/djp485
3. ME Charlson P Pompei KL Ales CR MacKenzie 1987 A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 373 383 3558716 10.1016/0021-9681(87)90171-8 1:STN:280:DyaL2s7ms1GnsQ%3D%3D (Pubitemid 17055592)
4. PM Ravdin KA Cronin N Howlader, et al. 2007 The decrease in breast-cancer incidence in 2003 in the United States N Engl J Med 356 1670 1674 17442911 10.1056/NEJMsr070105 1:CAS:528:DC%2BD2sXksFCltL0%3D (Pubitemid 46631679)
5. RT Chlebowski LH Kuller RL Prentice, et al. 2009 Breast cancer after use of estrogen plus progestin in postmenopausal women N Engl J Med 360 573 587 19196674 10.1056/NEJMoa0807684 1:CAS:528:DC%2BD1MXhsFyiur8%3D
6. B Fisher J Dignam N Wolmark, et al. 1999 Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 353 9169 1993 2000 10376613 10.1016/S0140-6736(99)05036-9 1:CAS:528:DyaK1MXkt1Cnsrk%3D (Pubitemid 29271743)
7. DC Allred J Bryant S Land, et al. 2002 Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in DCIS: findings from NSABP protocol B-24 (abstract 30) Breast Cancer Res Treat 76 S S36
8. B Fisher J Costantino C Redmond, et al. 1993 Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer N Engl J Med 328 22 1581 1586 8292119 10.1056/NEJM199306033282201 1:STN:280:DyaK3s3lsVCqug%3D%3D (Pubitemid 23151917)
9. BD Smith GL Smith TA Buchholz 2008 Controversies over the role of radiation therapy for ductal carcinoma in situ Expert Rev Anticancer Ther 8 433 441 18366290 10.1586/14737140.8.3.433 (Pubitemid 351836290)
10. ER Fisher SR Land RS Saad, et al. 2007 Pathologic variables predictive of breast events in patients with ductal carcinoma in situ Am J Clin Pathol 128 86 91 17580274 10.1309/WH9LA543NR76Y29J (Pubitemid 47121719)
11. MA Schonberg ER Marcantonio D Li RA Silliman L Ngo EP McCarthy 2010 Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival J Clin Oncol 28 2038 2045 20308658 10.1200/JCO.2009.25.9796
12. MJ Silverstein MD Lagios S Groshen, et al. 1999 The influence of margin width on local control of ductal carcinoma in situ of the breast N Engl J Med 340 19 1455 1461 10320383 10.1056/NEJM199905133401902 1:STN:280: DyaK1M3ktVShtw%3D%3D (Pubitemid 29220544)
13. D Krag D Weaver T Ashikaga, et al. 1998 The sentinel node in breast cancer-a multicenter validation study N Engl J Med 339 941 946 9753708 10.1056/NEJM199810013391401 1:STN:280:DyaK1cvhvVKntg%3D%3D (Pubitemid 28455095)
14. McLaughlin SA, Wright MJ, Morris KT et al (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26:5213-5219 [Erratum in: J Clin Oncol 2010; 28(10):1808]
15. B Fisher J Dignam N Wolmark, et al. 1999 Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 353 1993 2000 10376613 10.1016/S0140-6736(99)05036-9 1:CAS:528:DyaK1MXkt1Cnsrk%3D (Pubitemid 29271743)
16. TWF Yen KK Hunt Q Nadeem, et al. 2004 Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ Cancer 100 942 949 14983489 10.1002/cncr.20085 1:CAS:528:DC%2BD2cXitlehsL8%3D (Pubitemid 38222854)
17. Baum M, Budzar AU, Cuzick J et al (2002) ATAC Trialists'Group. Lancet 359(9324):2131-2139 [Erratum in: Lancet 2002; 360(9344):1520]